Re­gen­eron ends four clin­i­cal tri­als of its rolled-back Covid-19 an­ti­body

Re­gen­eron has ter­mi­nat­ed four stud­ies of its mon­o­clon­al an­ti­body com­bi­na­tion, known as RE­GEN-COV, in re­cent days, months af­ter the FDA halt­ed use of the drug for which the fed­er­al gov­ern­ment had doled out bil­lions of dol­lars, ac­cord­ing to the fed­er­al clin­i­cal tri­als data­base.

A BLA re­view for RE­GEN-COV has al­so gone be­yond the pre­vi­ous­ly ex­tend­ed PDU­FA date of Ju­ly 13, a com­pa­ny spokesper­son con­firmed to End­points News in an email.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER